Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Valsartan + chlorthalidone is a fixed-dose combination of two antihypertensive agents used primarily for the treatment of high blood pressure (hypertension). Valsartan is an angiotensin II receptor blocker (ARB) that works by blocking the action of angiotensin II, leading to vasodilation and reduced blood pressure. Chlorthalidone is a thiazide-like diuretic that reduces fluid retention by increasing renal excretion of sodium and water, which also helps lower blood pressure. The combination provides additive antihypertensive effects and may offer improved 24-hour blood pressure control compared to monotherapy with either agent alone[4]. Both drugs are well-established in clinical use for hypertension management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on valsartan + chlorthalidone.